Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316284 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1MAPTHTTGAA | |
| Iodide SCHEMBL9136386 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1PKMMAPTHTT | |
| SCHEMBL316151 | 0.79 | ALDH1A1 (0.57) | KDM4ESMN1; SMN2ALDH1A1PKMHPGD | |
| SCHEMBL5159327 | 0.77 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1PKMHPGD | |
| SCHEMBL31063748 | 0.73 | CA12 (0.35) | SMN1; SMN2ALDH1A1TDP1CA12CA1 | |
| SCHEMBL31063737 | 0.72 | CA9 (0.34) | SMN1; SMN2ALDH1A1MAPTLMNACA12 | |
| SCHEMBL316391 | 0.71 | MAPT (0.41) | KDM4ESMN1; SMN2ALDH1A1PKMHPGD | |
| SCHEMBL18230650 | 0.70 | GAA (0.45) | SMN1; SMN2ALDH1A1LMNAHTTGAA | |
| SCHEMBL159888 | 0.69 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2ALDH1A1PKMHPGD | |
| SCHEMBL9199430 | 0.69 | MAPT (0.53) | KDM4ESMN1; SMN2ALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670476-B2 | Enzyme substrate comprising a functional dye and associated technology and methods | BIOTIUM, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160237421-A9 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | BIOTIUM, INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-20140273151-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | BIOTIUM, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778627-B2 | Enzyme substrate comprising a functional dye and associated technology and methods | BIOTIUM, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8586325-B2 | Enzyme substrate comprising a functional dye and associated technology and methods | BIOTIUM, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130236888-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | BIOTIUM, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120115129-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | BIOTIUM, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8092784-B2 | Enzyme substrate comprising a functional dye and associated technology and methods | BIOTIUM, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090148386-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | BIOTIUM, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236888-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | ENGASE, GBA3, HSD17B14 | KDM4E 2980/4885SMN1; SMN2 2925/4885ALDH1A1 396/4885 |
| US-20120115129-A1 | ENZYME SUBSTRATE COMPRISING A FUNCTIONAL DYE AND ASSOCIATED TECHNOLOGY AND METHODS | ENGASE, GBA3, HSD17B14 | KDM4E 2980/4885SMN1; SMN2 2925/4885ALDH1A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.